亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

瑞典Cellartis AB
阿斯利康與瑞典Cellartis公司表示，二者已簽署了一項協(xié)議，延長目前正在進行的一項合作。該合作旨在開發(fā)基于人類胚胎干細胞生成的肝及心肌細胞的改良安全性篩選系統(tǒng)。

此次簽署的協(xié)議表明兩家公司將延長于2006年7月簽署的一項為期兩年的合作協(xié)議，該協(xié)議旨在研究從已建立的人類胚胎干細胞（hESC）生產(chǎn)線上獲得的細胞是否能夠被分化為機能人類肝細胞及心肌細胞。兩家公司表示：“分化技術(shù)的進一步改進，將使科學(xué)家能夠在藥物開發(fā)過程更早時期，更好地預(yù)測藥物的代謝以及其對人類肝及心臟可能產(chǎn)生的副作用。”

Cellartis首席執(zhí)行官Mats Lundwall表示，此項合作“目前正進入令人興奮的階段”，其還表示：“我們一直在通過此類交易確認我們作為hESC領(lǐng)域領(lǐng)軍人物的聲譽。”

阿斯利康負責開發(fā)事務(wù)的執(zhí)行副總裁Jan Lundberg表示：“如果我們能夠確實成功地建立一個分化胚胎干細胞的穩(wěn)定供應(yīng)，我們將能夠更準確地檢測出新藥的副作用。”其還表示：“這一突破可能會降低損耗率從而提高研發(fā)生產(chǎn)力，并最終為患者提供更安全的藥物。盡管依然存在重大科學(xué)障礙，但我們正在取得良好的進展并獲得寶貴的經(jīng)驗。”（


Cellartis AB is a Swedish/British biotechnology company focused on human embryonic stem (hES) cells and technology for drug discovery research, toxicity testing and regenerative medicine. The company is the world’s largest single source of ethically derived hES cell lines and has developed more than 30 ethically derived cell lines. The main business objective of Cellartis is to develop hepatocytes and cardiomyocytes from the proprietary stem cells for use as tools in drug discovery.

The company's strategy is to accelerate product development by working in partnership with academia and industry towards advanced stem cell products and technologies. Cellartis was founded in 2001 and is located in state of art facilities in G?teborg, Sweden and in Dundee, UK. The laboratories are prepared to meet the EU guidelines for current Good Manufacturing Practice (cGMP).

Moreover, Cellartis has implemented a quality system and laboratory standards that meet the foreseeable future demands. Cellartis is focused on quality and scale-up production, which are crucial success factors for future growth. Therefore, Cellartis has expanded its operation into automated cell production and built the world's first production facility to make large volumes of hES cells.

Cellartis welcomes strategic alliances and are actively seeking collaboration partners from the pharmaceutical and biotechnology industries.